Rotavirus is a major cause of death and the most common cause of severe diarrhea among children under the age of five in Africa.

To reduce the burden of disease, Burkina Faso decided to introduce the rotavirus vaccine in November 2013. To learn from the country’s experience, Merck asked AMP to conduct a study of the programmatic and logistical aspects of the vaccine introduction.

The three-month study is being conducted at national, regional, and district level and is based on interviews with Expanded Program on Immunization (EPI) managers. In particular, it will enable the identification of challenges related to the cold chain, vaccine supply, transportation, and vaccine acceptability, and highlight how they were overcome.

The results of the study will provide necessary feedback for other countries seeking to introduce rotavirus vaccine.